No evidence of a correlation between BCL10 expression and API2‐MALT1 gene rearrangement in ocular adnexal MALT lymphoma

Abstract

In the present study, 62 cases of ocular adnexal lymphoproliferative disorders were reviewed clinicopathologically. Of them, 51 were extranodal marginal zone B-cell lymphoma (MALT lymphoma), five were diffuse large B-cell lymphoma (DLBCL), one was peripheral T-cell lymphoma, one was NK/T cell lymphoma, nasal type, and four were reactive lymphoid hyperplasia. These lymphoma cases showed a favorable clinical course and localized disease, except for the case of NK/T cell lymphoma, although 19 cases (32.8%) had a recurrence of disease. To clarify the correlation between BCL10 protein expression and API2-MALT1 gene rearrangement, the 51 cases of MALT lymphoma and 5 cases of DLBCL were analyzed by immunohistochemical and RT-PCR methods. Nuclear BCL10 expression was identified in 58% of MALT lymphoma cases, but not in any DLBCL cases. There was no evidence of a correlation between aberrant nuclear BCL10 expression and the clinical parameters examined in the present study. API2-MALT1 transcription was not demonstrated in either the MALT lymphoma cases or the DLBCL cases studied using a multiplex one-tube reverse transcriptase-PCR method. These findings indicate that the nuclear expression of BCL10 is unlikely to correlate with the API2-MALT1 fusion gene in ocular adnexal MALT lymphoma.

Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options

“…11,13,18,23,27,28,30,36,37,39,[41][42][43][44][45][83][84][85] The male-female sex ratio is often less than 1, 11,23,27,28,30,36,37,[41][42][43][44][45]83,85 which distinguishes ophthalmologic lymphoma from the overall population of NHL, in which the male-female sex ratio is inversed 86 but is concordant with the sex ratio reported in MALT lymphoma, the most frequent histologic entity of all ocular NHLs. 29,87,88 In all published series except that by Cho et al, 42 the median age was approximately 65 years.…”

“…29,87,88 In all published series except that by Cho et al, 42 the median age was approximately 65 years. 11,13,18,23,27,28,30,36,37,39,41,[43][44][45][83][84][85] Few patients have B symptoms or a performance status (PS) greater than 1, though these findings are rarely reported in published series. 11,18,28,30,42,84 Lacrimal gland and intraorbital sites, observed in approximately 50% of patients, are the most frequent ophthalmologic sites.…”

“…11,13,18,22,23,27,28,[36][37][38][39][40][41][42][43][44][45][46][47] However, a large majority of reported OALs-between 95% and 100% of reported casescorrespond to the B-cell type, and 80% of B-cell lymphomas are low grade. A major characteristic of OAL is the high incidence of marginal zone B-cell lymphoma or mucosa-associated lymphoid tissue (MALT) lymphoma, reported in approximately 50% of patients.…”

Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and does not correlate with p65 NF-κB activation

“…19,27 Currently, the mechanism underlying this aberrant expression pattern is not understood, but BCL-10 gene mutation seems an unlikely cause. [27][28][29][30] Moderate nuclear BCL-10 expression, however, has been observed in some cases of MALT lymphoma without the t (11;18). 20,31,32 In addition, other B-cell lymphoproliferative disorders have been reported to express BCL-10 in a nuclear pattern although the staining is of moderate or weak intensity.…”

“…17,27 These findings are controversial, however, as other studies using immunohistochemistry or fluorescence in situ hybridization have failed to confirm BCL-10 nuclear expression in non-MALT lymphomas. [27][28][29] In this study, we were interested in assessing BCL-10 expression in LPL/WM, a neoplasm that has been rarely studied for BCL-10 expression in the past, most likely because these neoplasms are rare and primarily involve the BM. We identified aberrant nuclear expression of BCL-10 in more than half of the specimens.…”